In vivo synergy of radiation and hu14.18-IL2 immunocytokine results in a memory T cell response in a syngeneic murine melanoma model by unknown
POSTER PRESENTATION Open Access
In vivo synergy of radiation and hu14.18-IL2
immunocytokine results in a memory T cell
response in a syngeneic murine melanoma model
Zachary S Morris1*, Emily Guy1, David Francis1, Monica Gressett1, Richard Yang1, Alexander Rakhmilevich1,
Jaquelyn Hank1, Stephen Gillies2, Paul Harari1, Paul Sondel1
From Society for Immunotherapy of Cancer 29th Annual Meeting
National Harbor, MD, USA. 6-9 November 2014
Purpose
Tumor-specific monoclonal antibodies (mAb) are a com-
mon type of immunotherapy capable of engaging innate
immune cells to elicit antibody-dependent cell-mediated
cytotoxicity (ADCC). We recently demonstrated in vivo
synergy between radiation (RT) and ADCC using the
anti-GD2 hu14.18 mAb. We now investigate the poten-
tial of hu14.18-IL2 immunocytokine (IC) to augment this
synergy.
Method and materials
C57BL/6 mice were engrafted with syngeneic GD2-
expressing B78 melanoma. Macroscopic tumors (~ 200
mm3) were treated with sham or single fraction 12 Gy
RT. Mice then received 5 daily intra-tumor injections of
human IgG, hu14.18 mAb, or hu14.18-IL2 IC. NK or
T cell depletion was achieved by intraperitoneal injec-
tion of a depleting mAb (NK1.1 or CD4/CD8 mAbs).
After 90 days mice rendered disease-free by initial treat-
ment were re-challenged with a second injection of B78
melanoma. After an additional 30 days mice not devel-
oping tumors were injected at distinct sites with syn-
geneic B16 melanoma (related to B78 but lacking GD2)
and Panc02 pancreatic cancer cells.
Results
In tumor-bearing mice we observe synergy between RT
and anti-GD2 mAb resulting in tumor regression and
improved animal survival (Figure 1). This interaction of
RT and hu14.18 is inhibited by depletion of NK cells
and is not observed in mice that lack Fcϒ receptors.
Synergy is markedly enhanced by substituting mAb with
hu14.18-IL2 (Figure 2), resulting in durable complete
resolution of tumors in 71% (22/31) of animals. This
synergy of RT and IC is minimally affected by NK cell
depletion but is largely abrogated in nude mice and Fcϒ
receptor-deficient mice. Immunohistochemistry on post-
treatment tumor specimens demonstrates enhanced
recruitment of CD8+ T cells to tumors following com-
bined treatment with RT and IC. Of animals rendered
disease-free following combined treatment, 90% (18/20)
did not grow a tumor following a second injection with
B78 cells while no age-matched control mice (0/23)
rejected these cells. A subset of mice rendered disease-
free following initial treatment was later depleted of T
cells and none (0/5) rejected repeat engraftment with
B78 cells. Among mice rendered disease-free by initial
treatment and remaining disease-free after B78 re-chal-
lenge, 75% (9/12) rejected subsequent engraftment with
related GD2-deficient B16 melanoma cells. None of
these rejected simultaneous injection of Panc02 cells
and no age-matched controls (0/11) rejected the same
B16 cells.
Conclusion
We present evidence of synergy between RT and
hu14.18-IL2 resulting in a memory T cell response. Our
findings suggest a therapeutic opportunity for combin-
ing RT with immunotherapies that simultaneously target
innate immune response and T-cell activation.
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Figure 1 In vivo synergy of radiation and hu14.18K322A in a murine melanoma tumor model.
Figure 2 Enhanced in vivo synergy elicited by radiation and hu14.18-IL2 immunocytokine in a murine melanoma tumor model.
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